

Pharmacovigilance 2019: First Derivative Spectroscopic Method for Simultaneous Estimation of Edaravone and Citicoline Sodium in Synthetic Mixture

Arnav Ehsaan

Indian Institute of Technology Kharagpur

A straightforward, exact and exact spectroscopic technique was produced for concurrent estimation of Edaravone and Citicoline Sodium in engineered blend utilizing first request subsidiary zero-intersection strategy. Edaravone demonstrated zero intersection point at 245.60 nm while Citicoline Sodium indicated zero intersection point at 271.20 nm. The $dA/d\lambda$ was estimated at 271.20 nm for Edaravone and 271.20nm for Citicoline Sodium and adjustment bends were plotted as $dA/d\lambda$ versus focus, individually. The strategy was seen as straight ($r^2 > 0.999$) in the scope of 1-6 $\mu\text{g/ml}$ for Edaravone at 271.20 nm. The direct connection was acquired ($r^2 > 0.999$) in the scope of 25-150 $\mu\text{g/ml}$ for Citicoline Sodium at 271.20 nm. The constraint of assurance was 0.032 $\mu\text{g/ml}$ and 0.831 $\mu\text{g/ml}$ for Edaravone and Citicoline Sodium, individually. The constraint of measurement was 0.098 $\mu\text{g/ml}$ and 2.520 $\mu\text{g/ml}$ for Edaravone and citicoline Sodium, separately. The precision of these technique were assessed by recuperation studies and great recuperation result were gotten more prominent than 99% shows first request determination zero intersection. The technique was effectively applied for concurrent assurance of Edaravone and Citicoline Sodium in double blend.

Introduction: Edaravone (EDA) is a neuroprotective specialist utilized to help neurological recuperation following intense mind ischemia and ensuing cerebral dead tissue [1]. It goes about as a powerful cancer prevention agent and unequivocally rummages free radicals, ensuring against oxidative pressure and neuronal apoptosis [2,3,4]. It is chemically 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one. Edaravone is a white or grayish undefined powder having atomic weight 174.20g/mol [5-6] Chemical Structure of Edaravone is in

Citicoline (CIT), otherwise called cytidine diphosphate-choline (CDP-Choline) and cytidine 5'-diphosphocholine is a psychostimulant/nootropic. It is a

middle of the road in the age of phosphatidylcholine from choline. Citicoline's impacts may likewise be clarified by the decrease of phospholipase A2 movement. [7] Citicoline increments phosphatidylcholine combination

It is synthetically 5'-O[hydroxyl ({hydroxyl [2-(trimethylammonio) ethoxy]phosphoryl} oxy)phosphoryl] cytidine. Citicoline Sodium is a white or grayish shapeless, hygroscopic powder having sub-atomic weight 510.31g/mol [5, 6] Chemical Structure of Citicoline is in

The two medications are Neuroprotective specialists; Both medications are solvent in water. These medications will increment cerebral digestion and increment level of different synapses, including acetylcholine and dopamine, applying its activity by initiating the biosynthesis of basic phospholipids in neuronal film. This medication will build the blood stream and oxygen utilization in mind. At long last influence the CNS related turmoil.

The survey of writing with respect to quantitative examination of Edaravone and Citicoline Sodium uncovered that no endeavor was made to create diagnostic strategies for Edaravone and Citicoline Sodium. Some spectrometric strategies and chromatographic techniques have been accounted for the estimation of the individual medications [8-16]. The focal point of the current investigation was to create and approve a fast, steady, explicit, and financial RP-HPLC strategy for the estimation of Edaravone and Citicoline Sodium in Synthetic blend.

MATERIALS AND METHODOLOGY

- Edaravone and Citicoline Sodium were acquired as blessing tests from BDR Pharmaceutical global Pvt. Ltd. Engineered Mixture contain 1mg of Edaravone and 25mg of Citicoline Sodium.
- A twofold pillar UV/Visible spectrophotometer

(Shimadzu model 2450, Japan) with gashly width of 2 nm, 1 cm quartz cells was utilized to gauge absorbance of the considerable number of arrangements.

- Spectra were consequently gotten by UV-Probe framework programming.
- An expository parity (Sartorius CD2250, Gottingen, Germany) was utilized for gauging the examples.
- Sonicator(D120/2H, TRANS-O-SONIC)
- Class „A“ volumetric dish sets were utilized (Borosillicte) Standard stock answer for Edaravone

This gives a grouping of 100µg/ml in Distilled Water. Sonicated for 15min lastly volume was made sufficient with the dissolvable. From that 10ml was weakened in 100ml of Distilled Water and the volume was made up to 100ml which gives a centralization of 10µg/ml and from that 1ml was weakened with 10ml Distilled Water to acquired the fixation 1µg/ml for choice of logical frequency for ZCP strategy.

Standard stock answer for Citicoline Sodium

This gives a centralization of 250µg/ml in Distilled Water. From that 1ml was weakened in 10ml of Distilled Water and the volume was made up to 10ml which gives a grouping of 25µg/ml for choice of logical frequency for ZCP strategy.

Arrangement of Standard Mixture Solution (EDA + CIT) 1ml of standard stock arrangement of EDA (10µg/ml) and 1ml of standard Stock arrangement of CIT (250µg/ml) were pipetted out into two 10ml volumetric cups and volume was changed in accordance with the imprint with Distilled Water to get 1µg/ml of EDA and 25µg/ml of CIT.

Readiness of test arrangement

The readiness of manufactured blend was according to patent [17]:

- Water for Injection : 7.5 ml (at long last upto 10ml)
- Cystein HC1 : 0.75mg
- HydroxyPropyl Beta Cyclodextrene :100mg
- Edaravone : 10mg
- Sodium Bisulphite : 10mg

- Citicoline Sodium:250mg
- Disodium EDTA : 0.2mg

All the excipients were blended in 10ml volumetric jar and sonicated for 15min. make up the volume with Distilled Water. The arrangement was sifted through Whatman channel paper No. 42.

At long last the arrangement had fixation 100µg/ml for EDA and 2500µg/ml for CIT from that pipette out 2ml in 100ml volumetric flagon and make sufficient with Distilled Water.

75, 100µg/ml of CIT) and the %RSD of examine (between day and intra-day) was determined. The consequences of study are appeared in Table no 2 and 3.

Exactness

The exactness of the strategy was dictated by spiking of EDA and CIT to prequantified test arrangements of EDA (2µg/ml) and CIT (50µg/ml) in triplicate at three focus level of 80, 100, 120% of as far as possible. The rate recuperations of EDA and CIT were determined and the outcome is closer to 100% appeared in Table no 4 and 5.

Cutoff of Detection and Limit of Quantification

The constraint of location (LOD) and breaking point of quantitation (LOQ) of the strategy were assessed by standard deviation of reaction and slant technique. LOQ and LOD were determined by the condition $LOD = 3.3$

$\times N/B$ and $LOQ = 10 \times N/B$, where “N” is standard deviation of the absorbance, and “B” is the incline of the relating alignment bend.

Test

According to the test arrangement readiness, the arrangements were arranged and additionally continue for UV Spectrum.

A zero request subsidiary range of the subsequent arrangement was recorded and handled to first subordinate spectra. A first request subordinate range of the example arrangement was recorded and the absorbance at 271.20nm and 245.60nm were noted for estimation of EDA and CIT, separately.